Q-omics provides the consensus-scored CHST7 profile across patient tissues and cancer cell-line models. CHST7 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CHST7 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, CHST7 RNA expression shows 18,757 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and HNSC as cancer lineages where CHST7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHST7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHST7 survival associations across molecular data types. CHST7 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHST7 RNA expression–survival associations across cancer types. High CHST7 expression shows unfavorable associations in UVM and ACC, but favorable associations in KIRC, LUSC, SCLC and CESC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UVM as the clearest survival context for CHST7 RNA expression.
This table summarizes CHST7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CHST7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHST7 shows lower tumor expression in KICH, LUAD, BRCA and KIRP and higher tumor expression in HNSC and KIRC. The HNSC box plot shows higher CHST7 RNA expression in tumor versus normal tissue (log2 FC = +2.554, t-test p < 0.001).
This table shows molecular features associated with CHST7 in patient tissues and cancer cell lines. In patient samples, CHST7 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CHST7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BREAST.
